Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D00BLL
|
||||
| Former ID |
DNAP001676
|
||||
| Drug Name |
Fesoterodine fumarate
|
||||
| Synonyms |
Toviaz (TN)
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Overactive bladder disorder [ICD9: 188, 596.51; ICD10:C67, N32.81] | Approved | [1] | ||
| Company |
Pfizer
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C26H37NO3
|
||||
| Canonical SMILES |
CC(C)C(=O)OC1=C(C=C(C=C1)CO)C(CCN(C(C)C)C(C)C)C2=CC=CC=<br />C2
|
||||
| InChI |
1S/C26H37NO3/c1-18(2)26(29)30-25-13-12-21(17-28)16-24(25)23(22-10-8-7-9-11-22)14-15-27(19(3)4)20(5)6/h7-13,16,18-20,23,28H,14-15,17H2,1-6H3/t23-/m1/s1
|
||||
| InChIKey |
DCCSDBARQIPTGU-HSZRJFAPSA-N
|
||||
| CAS Number |
CAS 286930-03-8
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14781939, 17194959, 43529928, 51091564, 57371974, 74911026, 99443256, 114788164, 126633314, 126665680, 126666536, 127713256, 135215466, 137147467, 142600549, 151981129, 160682498, 160967872, 164841556, 174006830, 175268192, 176485080, 187051776, 210276627, 223666877, 224399961, 226492628, 241054700, 242587777, 252448583, 252552193
|
||||
| SuperDrug ATC ID |
G04BD11
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M1 | Target Info | Modulator | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Secretion of Hydrochloric Acid in Parietal Cells | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6. | ||||
| REF 2 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.